This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ulipristal acetate oral 30 mg

Updated 2 Feb 2023 | Emergency contraception


Tablet containing 30 mg ulipristal acetate

Drugs List

  • ELLAONE 30mg tablets
  • ulipristal 30mg tablets
  • Therapeutic Indications


    Emergency contraception (within 120 hours of intercourse)



    Take 30 mg (one tablet) as soon as possible, but no later than 120 hours (5 days) after unprotected intercourse or contraceptive failure.

    Tablet can be taken at any point in the menstrual cycle.


    Take 30 mg (one tablet) as soon as possible, but no later than 120 hours (5 days) after unprotected intercourse or contraceptive failure.

    Tablet can be taken at any point in the menstrual cycle.


    Severe hepatic impairment
    Severe uncontrolled asthma

    Precautions and Warnings

    Children under 18 years
    Glucose-galactose malabsorption syndrome
    Hepatic impairment
    Lactose intolerance

    Advise ability to drive/operate machinery may be affected by side effects
    Contains lactose
    Repeated use within one menstrual cycle is not advisable
    Exclude pregnancy prior to initiation of treatment
    If pregnancy occurs possibility of ectopic pregnancy should be considered
    Vomiting or severe diarrhoea may impair efficacy
    Advise patient not to take St John's wort concurrently
    Female: Barrier contraception recommended for the rest of the monthly cycle
    Advise patient early or late onset of next menstrual period is possible
    Take another dose if vomiting occurs within 3 hours

    Pregnancy and Lactation


    Ulipristal acetate is contraindicated in pregnancy.

    Extremely limited data are available on the health of the foetus/newborn in case a pregnancy is exposed to ulipristal acetate. Although no teratogenic potential was observed, animal data are insufficient with regard to reproduction toxicity.

    The manufacturer has requested that healthcare providers inform them of the outcome of any pregnancies that occur despite treatment with ulipristal acetate, including undetected pregnancies at the time of treatment or pregnancies that occurred due to treatment failure. The information should be recorded at the pregnancy registry website at

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Use ulipristal acetate with caution in breastfeeding.

    Ulipristal acetate is excreted in breast milk. The effect on newborn/infants has not been studied. A risk to the breastfed child cannot be excluded. The manufacturers recommend that breastfeeding is withheld for one week after taking ulipristal acetate, during this time breast milk should be expressed and discarded in order to stimulate lactation. However, the UK Medicines Information (UKMi) suggest that withholding breastfeeding is not necessary as the risk to the newborn/infant is low.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at


    Advise patient that ulipristal should not be taken with levonorgestrel emergency contraception.

    Advise patient the ulipristal has to be taken within 120 hours of unprotected intercourse and that pregnancy will not be prevented in all cases.

    If vomiting occurs within 3 hours of ulipristal acetate intake, another tablet should be taken.

    If patient is using hormonal contraception, advise her that additional barrier methods should be used until the next menstrual period starts.

    Advise patient that pregnancy must be excluded before treatment.

    Advise patient that after ulipristal acetate intake menstrual periods can sometimes occur earlier or later than expected by a few days. In some cases this has been observed up to 20 days.

    Side Effects

    Abdominal pain
    Abnormal sensation in eye
    Attention disturbances
    Back pain
    Bladder pain
    Breast pain
    Changes in libido
    Chest discomfort
    Conjunctival infection
    Disturbances of appetite
    Dry mouth
    Dry throat
    Extremity pain
    Gastroesophageal reflux disease
    Genital pain
    Genital pruritus
    Hot flushes
    Menstrual disturbances
    Mood changes
    Muscle spasm
    Musculoskeletal pain
    Nasal congestion
    Ocular hyperaemia
    Ovarian cysts
    Pelvic inflammatory disease
    Premenstrual-like syndrome
    Renal pain
    Skin lesions
    Sleep disturbances
    Tooth ache
    Urinary tract disorders
    Urinary tract infections
    Vaginal discharge
    Vaginal haemorrhage
    Visual disturbances


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2015

    Reference Sources

    Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 02 June 2015.

    Summary of Product Characteristics: EllaOne 30 mg tablet. HRA Pharma UK Ltd. Revised January 2015.

    UK Medicines Information. UKMi Medicines Q&As
    Last accessed: 03 June 2015

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.